feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Alzinova: Interim Data From Phase Ib Study
Research Note
2022-12-13
09:42
Redeye comments on the new positive safety review and interim data from the ongoing phase Ib study with vaccine candidate ALZ-101.
KS
Kevin Sule
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans